Why Is It Important To Pursue A Career In Biotechnology?

What field/program are you studying at Guilford Technical College and why did you choose it?

Maintained outstanding communication and analytical capabilities along with interpersonal skills to share information with clients and team members.

This can connect to problem-solving, they need to find what’s wrong, how to fix the problem, and how much it will cost. They also have to know how to working with people so you know how to approach people and watch how the people react. Last, they need to managing their time/information so they can work on two or more thing at once and keep the information in the right

In Joel Lexchin’s article “Pharmaceutical innovation: Can we live forever? A commentary on Schnittker and Karandinos” he addresses the article made by Schnittker and Karandinos about the progression of pharmaceuticals and whether or not we have advanced enough to significantly increase our life expectancy. Lexchin uses a plethora of rhetoric to persuade the reader into believing his argument, mostly relying upon logos, chiefly facts, to appeal to the logical and sensible side of the readers. His argument is not limited to logos though, as there are faint traces of pathos, the longing to live forever, as well as ethos, society’s needs for further advances, to further convince the reader.

Consequently, all team members were selected according to their talents and skill level. How well they communicate with written and verbal communication. According to Cheesebro, (2010) the ability to solve problems and think critically are good traits to have. They have a desire to accomplish the task and be held accountable for their performance.

In the year of 2017, I would think 99% of the population of the Western world would believe in the life saving abilities and precautions vaccines are able to provide. But recently, a new wave of danger has befallen the mommy bloggers and soccer moms. The fear of bearing autistic children ‘brought about by vaccines’ is too much for these moms, they couldn’t watch their child suffer such a fate. So what’s their solution to protect their precious miracle? Ultimately, sacrificing the overall physical health of the child, as well as the children around them by depriving the child of a good, healthy start in infancy in exchange for non-medical protection. One making such an ill-informed, naive, and selfish decision for their child ultimately

Molecular Cell Biology, 7th Edition, 2013, Lodish, Berk, Kaiser, Krieger, Bretscher. Ploegh, Amon, and Scott. W.H. Freeman and Company (ISBN-13: 978-1-4292-3413-9)

This commentary will provide a reflection of the author’s key skill competencies, particularly focusing on communication, teamwork, problem-solving, interpersonal skill. A summary of these keys skills will outline the author’s key strengths and areas for future improvement relative to either current weaknesses and or challenges.

Located in South San Francisco, CA, Genentech was started in 1976 by a biochemist Dr. Herbert Boyer and Robert A. Swanson. From 1995-2009 Arthur Levinson had become the CEO of Genentech; presently it is Ian T. Clark. Genentech is a leading biotechnology company, using human genetic information to discover, develop, manufacture and commercialize medicines to treat people with serious or life-threatening medical conditions (2014). Biotechnology is the technology based on the science of cellular and biomolecular processes to develop technologies and products that help improve peoples’ lives and the health of our environment. How biotechnology uses cellular and biomolecular processes are by using molecular mechanisms by which genetic and

Everyone is drawn to confidence; it’s a proven fact. Although, you also want to make

Cambridge Sciences Pharmaceuticals (CSP) is an international healthcare company based in Cambridge, Massachusetts. The firm focuses on developing, manufacturing and marketing products that treat metabolic disorders, gastrointestinal diseases, immune deficiencies, as well as other chronic medical conditions. In 2008, CSP received its Food and Drug Administration (FDA) approval for its newest prescription drug, Metabical. Metabical is a drug that offers moderately overweight adults a medically proven, effective method to reach a desirable weight to improve their overall health by shedding ten to thirty pounds.

The book From Alchemy to IPO: the business of Biotechnology (2001) was a wonderful read. Although a little outdated (before the 2008 financial crisis), Cynthia Robbins-Roth was able to capture the thrill of starting the first biotech companies, the struggle to keep the companies afloat during down markets, as well as the elation of success when a company succeeds where others failed. I was astounded that any new company could survive the decade long march to putting their first product on the market, but Robbins-Roth provided direct quotations from the major investors that stuck with the market when most other investors had pulled out. These quotes, by the end of the book, gave me a much better understanding not only of the biotech industry but also the mentality of the major investors in the field. Although the sector is teeming with risky investments, if you educate yourself about the companies and understand the science involved, and be ready for the long-haul it is possible to lower your risk to reasonable levels.

Biotechnology is a broad term. Basically, it is the “tools and techniques [opening] new research avenues for discovering how healthy bodies work and what goes wrong when problems arise”(Siedler para. 1). It covers controversial technology and procedure, like genetic engineering and gene therapy. It is controversial because it can affect everyone(Jeremy para. 16). As a consequence, the development of biotechnology has been a “slow, quiet progress”(Kirsner para. 3) because society may or may not recognize the repercussion of it. However, scientist like Smith- a previous chief for the Cambridge biotech company, Genzyme- continues to develop biotechnology(para. 1). Because biotechnology can be controversial, yet scientist continues to develop it;

practices, learning, motivation, reward, selection – those are the strategic choices…to make” - Geoff Armstrong, CIPD. Aside from this, what other skills and qualities

In 2005, Phillip (Phil) Landgraf faced several glaring problems in the financial performance of his company, BioPharma, Inc. The firm had experienced a steep decline in profits and very high costs at its plants in Germany and Japan. Landgraf, the company 's president for worldwide operations, knew that demand for the company 's products was stable across the globe. As a result, the surplus capacity in his global production network looked like a luxury he could no longer afford.